Tag: Corporate

MONTRÉAL, 25 juin 2025 (GLOBE NEWSWIRE) -- Boralex inc. (« Boralex » ou la « Société ») (TSX : BLX) est fière d’annoncer qu’elle s’est classée au premier rang du palmarès annuel des « 50 meilleures entreprises citoyennes » ("Best 50 Corporate Citizens") au Canada de Corporate Knights. Ce classement récompense les compagnies se démarquant par leur leadership et leur engagement en matière de développement durable. Cette reconnaissance souligne l’importance que Boralex accorde à la responsabilité sociétale, qui est au cœur de sa stratégie d’affaires.

JERICHO, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- Kimco Realty^® (NYSE: KIM) will announce its second quarter 2025 earnings on July 31, 2025, before market open. You are invited to listen to our quarterly earnings conference call. The webcast information is as follows:

In accordance with section 30 of the Capital Markets Act, Pandora A/S hereby announces that
BlackRock, Inc. has notified the company that it now holds 7,485,780 shares, corresponding to 9.47% of the total voting rights and share capital (previously 9.51%). Additionally, BlackRock, Inc. controls voting rights attached to financial instruments amounting to 0.50% (previously 0.49%). In total, BlackRock, Inc. control 9.98% of the company’s voting rights (previously 10.01%).

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.

LEI: 213800NNT42FFIZB1T09 
25 June 2025

What you need to know:

NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS).

NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Red Cat Holdings, Inc. (NasdaqCM: RCAT), if they purchased the Company’s securities between March 18, 2022 and January 15, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.

NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (NYSE: OGN), if they purchased the Company’s securities between October 31, 2024 and April 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.